Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
HELE heads into its October 7 earnings release with bears maintaining a meaningful position even as the stock has shed 10% in the past week alone.
Short interest is the clearest signal going into the print. Bears hold 12.6% of the free float, a level that qualifies as genuinely high, and that position has grown steadily over the past month, up roughly 3% in shares short. Days to cover runs close to nine, meaning any sharp move higher could create real pressure to unwind. The borrow market tells a contrasting story, however: availability is extremely loose at 936%, meaning there are roughly nine shares available to borrow for every one already lent out, and the cost to borrow is a modest 0.63%. New shorts face no friction entering the trade.
Options positioning is unremarkable. The put/call ratio is 0.75, sitting fractionally below its 20-day average and well within normal range. There is no elevated demand for downside protection heading into the release, which is unusual given both the weight of short interest and the stock's 11% slide over the past month to $25.32. That mismatch, shorts in size but options traders relaxed, is itself a notable feature of the setup.
The analyst community is uniformly cautious but not alarmed. Every major covering firm holds a hold or neutral rating, with Canaccord Genuity raising its target to $26 yesterday, a token move that barely clears the current price, while UBS sits at $28. The consensus mean target of $31.33 implies about 24% upside from here, but given the stock traded above $40 earlier in 2026 before losing more than a third of its value, that target reflects a cluster of analysts who raised and then cut as the story deteriorated. The bear case centres on a projected 10% sales decline driven by softer consumer demand in beverageware and home products, tariff-driven order cancellations from direct importers, and pressure on the closeout channel. Bulls point to eight of eleven brands posting point-of-sale unit growth in the US, selective price increases, and a normalised cold and flu season as potential tailwinds for the health and home segment.
One feature of the ownership register worth noting: FMR filed an amended 13G in August 2025 showing its stake had fallen to effectively zero from 11.3% previously, while AQR Capital filed a fresh 13G in August 2026 disclosing a 5.68% position. These are passive disclosures triggered around the 5% threshold, and stakes are as last disclosed, so actual current positions may differ. BlackRock reported an 8.1% holding as recently as September 30, making it the largest known institutional presence heading in.
The print is therefore a test of whether management's brand-level momentum can offset the structural headwinds in its weakest categories, and whether any guidance reset is already in the price after a stock that halved from its 2026 peak.
See the live data behind this article on ORTEX.
Open HELE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
